Pentixapharm Holding AG (XTER:PTP) Interest Coverage: 0 (At Loss) (As of Mar. 2026)


XTER:PTP Pentixapharm Holding AG XTER:PTP
12 GF Score
Price €2.37
! 5 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Interest Coverage?

Pentixapharm Holding AG XTER:PTP +12.86% 12 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, Pentixapharm Holding AG ranks worse than 265251.72% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Pentixapharm Holding AG's Operating Income for the three months ended in Mar. 2026 was €-3.04 Mil. Pentixapharm Holding AG's Interest Expense for the three months ended in Mar. 2026 was €-0.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Pentixapharm Holding AG's Interest Coverage or its related term are showing as below:


XTER:PTP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pentixapharm Holding AG  (XTER:PTP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Pentixapharm Holding AG Interest Coverage Related Terms

Pentixapharm Holding AG Interest Coverage Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Pentixapharm Holding AG Interest Coverage Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 No Debt 0.00 0.00 No Debt

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only No Debt 0.00 No Debt No Debt 0.00

XTER:PTP vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Pentixapharm Holding AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pentixapharm Holding AG Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's Interest Coverage falls into.


XTER:PTP
12GF Score
Pentixapharm Holding AG XTER:PTP
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pentixapharm Holding AG's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Pentixapharm Holding AG's Interest Expense was €0.00 Mil. Its Operating Income was €-19.59 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Pentixapharm Holding AG had no debt (1).

Pentixapharm Holding AG's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Pentixapharm Holding AG's Interest Expense was €-0.03 Mil. Its Operating Income was €-3.04 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Pentixapharm Holding AG did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Pentixapharm Holding AG (XTER:PTP) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pentixapharm Holding AG and its competitors. According to the industry distribution chart, Pentixapharm Holding AG ranks #999999 out of 377 companies in the Biotechnology industry.
Is Pentixapharm Holding AG's Interest Coverage too high?
Pentixapharm Holding AG's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Pentixapharm Holding AG ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pentixapharm Holding AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #999999 out of 377 companies for Interest Coverage. This places Pentixapharm Holding AG in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Pentixapharm Holding AG's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
12GF Score

Get the complete analysis for XTER:PTP

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.37
Price